Cadrenal Therapeutics to Participate in the 2023 BIO CEO & Investor Conference
PONTE VEDRA, Fla., Feb. 6, 2023 — Cadrenal Therapeutics, Inc. (Nasdaq: CVKD), a biopharmaceutical company focused on developing tecarfarin, a clinical-stage novel cardiorenal therapy with orphan drug and Fast Track designations, today announced that Chairman and Chief Executive Officer, Quang Pham, is available for one-on-one meetings at the BIO CEO & Investor Conference taking place […]
Cadrenal Therapeutics Announces Formation of Scientific Advisory Board
PONTE VEDRA, Fla., Feb. 1, 2023 — Cadrenal Therapeutics, Inc., (Nasdaq: CVKD) a biopharmaceutical company focused on developing tecarfarin, a clinical-stage novel cardiorenal therapy with orphan drug and Fast Track designations, announced today the formation of its Scientific Advisory Board (SAB) in support of the development of tecarfarin for the prevention of systemic thromboembolism, more […]
Cadrenal Therapeutics (Nasdaq: CVKD) Announces Closing of Initial Public Offering
Cadrenal Therapeutics (Nasdaq: CVKD) Announces Closing of Initial Public Offering PONTE VEDRA, Fla., Jan. 24, 2023 /PRNewswire/ — Cadrenal Therapeutics, Inc. (Nasdaq: CVKD), a biopharmaceutical company focused on developing tecarfarin, a clinical-stage novel cardiorenal therapy with orphan drug indication, today announced the closing of its initial public offering of 1,400,000 shares of common stock at a public offering price […]
Cadrenal Therapeutics (Nasdaq: CVKD) Granted FDA Fast Track Designation for Tecarfarin for Prevention of Systemic Thromboembolism of Cardiac Origin in Patients with End-Stage Renal Disease and Atrial Fibrillation
Cadrenal Therapeutics (Nasdaq: CVKD) Granted FDA Fast Track Designation for Tecarfarin for Prevention of Systemic Thromboembolism of Cardiac Origin in Patients with End-Stage Renal Disease and Atrial Fibrillation PONTE VEDRA, Florida – January 23, 2023 – Cadrenal Therapeutics, Inc., a biopharmaceutical company focused on developing tecarfarin, a clinical-stage novel cardiorenal therapy with orphan drug designation, announced […]
Cadrenal Therapeutics Announces Pricing of Initial Public Offering (IPO)
Cadrenal Therapeutics Announces Pricing of Initial Public Offering (IPO) PONTE VEDRA, Florida – January 20, 2023 – Cadrenal Therapeutics, Inc., a biopharmaceutical company focused on developing tecarfarin, a clinical-stage novel cardiorenal therapy with orphan drug designation, announced today the pricing of its initial public offering of 1,400,000 shares of common stock at a public offering price […]
American Heart Association Scientific Sessions | November 5-7, 2022
Cadrenal to attend the American Heart Association (AHA) Scientific Sessions on November 5-7, 2022 in Chicago, Illinois. Conference Link: https://professional.heart.org/es/meetings/scientific-sessions
American Society of Nephrology: Kidney Week 2022 | November 3-6, 2022
Cadrenal to attend ASN Kidney Week 2022 on November 3-6, 2022 in Orlando, Florida. Conference Link: https://www.asn-online.org/education/kidneyweek/
BioFlorida Annual Conference | November 2-4, 2022
Cadrenal to attend the BioFlorida Annual Conference on November 2-4, 2022 in Miami, Florida. Conference Link: https://www.bioflorida.com/events/EventDetails.aspx?id=1633993&group=
BIO International Convention | June 13-16, 2022
Cadrenal to attend the BIO International Convention on June 13-16, 2022 in San Diego, California. Conference Link: https://www.bio.org/events/bio-international-convention
Cadrenal Therapeutics Announces Appointment of Douglas Losordo, MD as Chief Medical Officer
Cadrenal Therapeutics Announces Appointment of Douglas Losordo, MD as Chief Medical Officer PONTE VEDRA, Florida – July 25, 2022 –Cadrenal Therapeutics, Inc. (“Cadrenal”), a biopharmaceutical company focused on developing tecarfarin, a clinical-stage novel cardiorenal therapy with orphan drug indication, today announced the appointment of Douglas W. Losordo, MD, FACC, FAHA as Chief Medical Officer. Quang […]
